Altimmune to Present at Upcoming Investor Conferences
H.C. Wainwright4th Annual NASH Investor Conference Monday, October 5, 2020– 3:30 pm ET
- Guggenheim Securities’ 1st Annual Vaccines & Infectious Diseases Day
Monday, October 5, 2020– 4:45 pm ET
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.
|Altimmune, Investor Relations|
Source: Altimmune, Inc.